<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Chlorpropamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00672</strong>&#160; (APRD00029)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (<span class="caps">NIDDM</span>). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating &#946; cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic &#946; cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of <span class="caps">NIDDM</span> as it increases blood pressure and the risk of retinopathy (<span class="caps">UKPDS</span>-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00672/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00672/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00672.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00672.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00672.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00672.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00672.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00672">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Chlorpropamid</td><td>German</td><td>INN</td></tr><tr><td>Chlorpropamide</td><td>French</td><td>INN</td></tr><tr><td>Chlorpropamidum</td><td>Latin</td><td>INN</td></tr><tr><td>Clorpropamida</td><td>Spanish</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abemide</td><td>Kobayashi Kako</td></tr><tr><td>Chloronase</td><td>Hoechst</td></tr><tr><td>Chlorpropamide</td><td>Mylan</td></tr><tr><td>Dabinese</td><td>Pfizer</td></tr><tr><td>Diabeedol</td><td>Sriprasit Dispensary</td></tr><tr><td>Diabemide</td><td>Guidotti</td></tr><tr><td>Diabezin</td><td>Prince</td></tr><tr><td>Diabinese</td><td>Pfizer</td></tr><tr><td>Diabitex</td><td>Plantex-Ikapharm</td></tr><tr><td>Dibecon</td><td>Pharmasant</td></tr><tr><td>Glycemin</td><td>Siam Bheasach</td></tr><tr><td>Hypomide</td><td>Aspen Pharmacare</td></tr><tr><td>Litangen</td><td>Ming Ta</td></tr><tr><td>Propamide</td><td>Atlantic</td></tr><tr><td>Trane</td><td>Omega</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Bidiabe</td><td>Chlorpropamide and Phenformin</td></tr><tr><td>Chlorformin</td><td>Chlorpropamide and Phenformin</td></tr><tr><td>Fenclor</td><td>Chlorpropamide and Phenformin</td></tr><tr><td>Insogen Plus</td><td>Chlorpropamide and Metformin</td></tr><tr><td>Obinese </td><td>Chlorpropamide and Metformin</td></tr><tr><td>Pleiamide</td><td>Chlorpropamide and Metformin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypoglycemic-agents">Hypoglycemic Agents</a></li>
<li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>94-20-2</td></tr><tr><th>Weight</th><td>Average: 276.74<br>Monoisotopic: 276.033540689</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>RKWGIWYCVPQPMF-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(4-chlorobenzene)sulfonyl]-3-propylurea</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzenesulfonamides</td></tr><tr><th>Direct parent</th><td>Benzenesulfonamides</td></tr><tr><th>Alternative parents</th><td>Sulfonylureas; Chlorobenzenes; Aryl Chlorides; Sulfonamides; Sulfonyls; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; sulfonylurea; aryl halide; aryl chloride; sulfonamide; sulfonic acid derivative; sulfonyl; polyamine; organohalogen; organochloride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of NIDDM in conjunction with diet and exercise. </td></tr><tr><th>Pharmacodynamics</th><td>Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide.</td></tr><tr><th>Mechanism of action</th><td>Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.</td></tr><tr><th>Absorption</th><td>Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Highly bound to plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Up to 80% of dose is metabolized likely through the liver to to 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced by decomposition in urine. It is unknown whether chlorpropamide metabolites exert hypoglycemic effects. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Chlorpropamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00199">2-Hydroxychlorpropamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/200">Details</a></td></tr><tr><td>Chlorpropamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00200">3-Hydroxychlorpropamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/201">Details</a></td></tr><tr><td>Chlorpropamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00201"><i>p</i>-Chlorobenzene sulfonylurea</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/202">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00201"><i>p</i>-Chlorobenzene sulfonylurea</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00977"><i>p</i>-Chlorobenzene sulfonamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1511">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours. </td></tr><tr><th>Half life</th><td>Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>IPN-RAT LD<sub>50</sub> 580 mg/kg</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9969</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8087</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6198</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6087</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9009</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9533</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8747</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Substrate</td>
        <td>0.5553</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8806</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7042</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9044</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9592</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6454</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7685
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9206
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1413 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9072
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9306
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Barr laboratories inc</li>
<li>Clonmel healthcare ltd</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Halsey drug co inc</li>
<li>Ivax pharmaceuticals inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Superpharm corp</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Usl pharma inc</li>
<li>Watson laboratories inc</li>
<li>Pfizer laboratories div pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>100 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>250 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Diabinese 250 mg tablet</td><td>1.34USD</td><td>tablet</td></tr><tr><td>Diabinese 100 mg tablet</td><td>0.61USD</td><td>tablet</td></tr><tr><td>Chlorpropamide 250 mg tablet</td><td>0.46USD</td><td>tablet</td></tr><tr><td>Chlorpropamide 100 mg tablet</td><td>0.33USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>129.2-129.8</td><td>McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co.,
Inc.</td></tr><tr><td>water solubility</td><td>258 mg/L (at 37 &#176;C)</td><td>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</td></tr><tr><td>logP</td><td>2.27</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>logS</td><td>-3.03</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>5.13</td><td>LIPINSKI,CA ET AL. (1991)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.57e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.15</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.94</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>4.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>75.27</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>65.43</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>27.06</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co.,<br>
Inc.</p></span></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00271" target="_blank">D00271 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2727" target="_blank">2727 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506402" target="_blank">46506402 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2626.html" target="_blank">2626 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3650" target="_blank">3650 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL498" target="_blank">CHEMBL498 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000923" target="_blank">DAP000923 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448966" target="_blank">PA448966 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=156728" target="_blank">156728 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/chlorpro.htm" target="_blank">http://www.rxlist.com/cgi/generic2/chlorpro.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/chlorpropamide.html" target="_blank">http://www.drugs.com/cdi/chlorpropamide.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Chlorpropamide" target="_blank">Chlorpropamide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A10BB02<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A10#A10">A10 &#8212; DRUGS USED IN DIABETES</a></li><li><a href="/atc/A10B#A10B">A10B &#8212; BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS</a></li><li><a href="/atc/A10BB#A10BB">A10BB &#8212; Sulfonamides, urea derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>68:20.20</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00672.pdf?1265922734">show</a>(35.8 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00636">Clofibrate</a></td><td>Clofibrate may increase the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB01119">Diazoxide</a></td><td>Antagonism. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Dicumarol may increase the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01296">Glucosamine</a></td><td>Possible hyperglycemia</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>The beta-blocker, practolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00052">Somatropin recombinant</a></td><td>Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01298">Sulfacytine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB01299">Sulfadoxine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB01581">Sulfamerazine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB01582">Sulfamethazine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00576">Sulfamethizole</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB01015">Sulfamethoxazole</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00891">Sulfapyridine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00795">Sulfasalazine</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00263">Sulfisoxazole</a></td><td>Sulfonamide/sulfonylurea: possible hypoglycemia</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The beta-blocker, timolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Food reduces the rate of absorption.</li>
<li>Take 30 minutes before meal.</li></ul></td></tr></tbody></table>